Post-marketing studies are a critical phase in the oncology drug lifecycle, generating real-world evidence on safety, efficacy, and long-term outcomes. For pharmaceutical and biotechnology partners, these studies are essential for fulfilling regulatory commitments, supporting label expansions, and informing clinical adoption. Leveraging deep expertise in both clinical and translational science, Alfa Cytology delivers integrated post-marketing research services tailored to the distinct challenges of cancer therapeutics, bridging rigorous clinical investigation with the complexities of real-world oncology care.
A post-marketing study is conducted after a therapy receives regulatory approval. These studies gather additional data on a product's safety profile, optimal use, and effectiveness in broader, more diverse patient populations than those included in pre-approval trials. Beyond fulfilling regulatory requirements such as post-marketing requirements (PMRs) or commitments (PMCs), these studies generate evidence that informs clinical guidelines, payer decisions, and long-term therapeutic positioning. In oncology, where therapy paradigms evolve rapidly and patient heterogeneity is pronounced, post-marketing studies are indispensable for defining a therapy's full risk-benefit profile in real-world clinical practice.
Fig.1 Overview of post-approval dose optimization strategies. (Soltantabar, P., et al., 2023)
Post-marketing studies in oncology encompass a range of interventional and non-interventional designs, each selected based on the research question, regulatory context, and data requirements. The choice of design directly influences the quality of evidence generated for safety surveillance, comparative effectiveness, and long-term outcomes. Common study types include the following.
Observational Studies
Non-interventional designs, including prospective and retrospective cohort studies, that capture real-world therapy patterns, long-term safety outcomes, and comparative effectiveness.
Registry-Based Studies
Patient or disease registries that systematically collect longitudinal data to monitor rare adverse events, survival outcomes, and therapy utilization in defined populations.
Post-Authorization Safety Studies (PASS)
Targeted investigations focused on characterizing known risks or identifying previously unrecognized safety signals in larger or underrepresented populations.
Post-Authorization Efficacy Studies (PAES)
Studies designed to confirm or further characterize clinical benefit, such as long-term outcomes or label expansion, are often conducted in real-world settings or specific subpopulations.
In oncology, post-marketing studies bridge the gap between controlled trial conditions and real-world clinical practice, providing evidence that directly impacts patient care and commercial success.
Built upon a foundation of deep scientific expertise in oncology and a robust operational infrastructure, Alfa Cytology offers comprehensive post-marketing research solutions that span study design, global execution, and integrated data analytics to meet the specific requirements of global pharmaceutical and biotechnology partners, facilitating the continued success of innovative cancer therapies. From regulatory-grade safety studies to real-world evidence generation, the approach ensures that each study delivers insights aligned with therapeutic goals.
A structured, phase-driven approach ensures that post-marketing studies are executed with scientific rigor, operational efficiency, and regulatory alignment from concept through final deliverables. Each phase is designed to anticipate challenges specific to oncology research, including complex endpoints, diverse data sources, and evolving therapy landscapes.
A full suite of post-marketing research services addresses the diverse objectives of oncology drug lifecycle management, ranging from regulatory commitments to evidence generation for clinical adoption. Each service type is delivered with specialized expertise in oncology research and real-world evidence.
Phase IV Trials for Approved Indications and Populations
Interventional studies conducted post-approval to fulfill regulatory requirements, further characterize safety and efficacy, or support additional patient populations.
Drug Safety and Effectiveness Studies
Comprehensive evaluations of therapeutic risk-benefit profiles in real-world settings, including comparative effectiveness assessments and long-term outcome analyses.
Pharmacoeconomic and Outcomes Research
Research designed to assess the economic impact of oncology therapies, including cost-effectiveness, resource utilization, and value-based outcomes for payers and formulary decision-makers.
Pharmacovigilance and Adverse Event Monitoring
Centralized surveillance programs focused on systematic collection, evaluation, and reporting of adverse events to support ongoing safety assessments.
Real-World Evidence Studies for Marketed Products
Observational and pragmatic studies leveraging electronic health records, claims data, and registries to generate evidence on therapy patterns, clinical outcomes, and product performance in routine practice.
Investigator-Initiated Trial Support
Collaborative partnerships supporting independent research proposals from investigators, with full operational support to advance scientific inquiry into novel uses, combinations, or biomarker-driven questions.
With deep domain expertise spanning solid tumors and hematologic malignancies, Alfa Cytology delivers post-marketing study solutions precisely tailored to the distinct biological drivers, therapy landscapes, and clinical heterogeneity that define each disease. The portfolio of experience encompasses a broad spectrum of cancers.
Post-marketing study strategies are not one-size-fits-all; they must be precisely tailored to the distinct biological mechanisms, safety profiles, administration requirements, and clinical utilization patterns of each therapeutic modality. Our expertise spans a comprehensive range of oncology therapy approaches, and comprehensive research support is provided for an extensive array of therapeutic interventions, reflecting the current shift toward precision oncology and the integration of complex biological platforms.
Delivering evidence that matters, from fulfilling regulatory commitments to shaping clinical practice, Alfa Cytology provides end-to-end post-marketing research services purpose-built for oncology. Every study is designed to generate the robust, real-world evidence required to define a therapy's long-term value. Contact our team to discuss how post-marketing research capabilities can support strategic lifecycle management objectives.
Reference
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.